Results 81 to 90 of about 315,361 (205)

Rituximab in kidney disease and transplant

Animal Models and Experimental Medicine, 2019
Rituximab is a chimeric monoclonal antibody that binds to CD20 antigen of B‐cells. It depletes the level of mature B‐cells by various mechanisms such as mediation of antibody‐dependent cellular cytotoxicity, complement‐dependent cytotoxicity, and B‐cell ...
Kajal Chauhan, Anita A. Mehta
doaj   +1 more source

Induction of IL 2 receptor expression and cytotoxicity of thymocytes by stimulation with TCF1 [PDF]

, 1985
We investigated the role of T cell cytotoxicity inducing factor 1 (TCF1) in the induction of a cytotoxic T cell response. We found that help-deficient thymocyte cultures supplied with saturating amounts of purified IL 2 did not develop CTL in a 5-day ...
Diamantstein, T., Dröge, W., Falk, Werner, Kaltmann, B., Katzer, B., Krammer, P. H., Männel, D. N.   +6 more
core  

Characterization of anti-canine CD20 antibody 4E1-7-B_f and comparison with commercially available anti-human CD20 antibodies.

PLoS ONE
This study characterizes the previously reported anti-canine CD20 antibody 4E1-7-B_f and compares this with commercially available anti-human CD20 antibodies, rituximab and an obinutuzumab biosimilar.
Takuya Mizuno, Yukinari Kato, Toshihiro Tsukui, Masaya Igase   +3 more
doaj   +1 more source

Loss of testosterone impairs anti-tumor neutrophil function. [PDF]

, 2020
In men, the incidence of melanoma rises rapidly after age 50, and nearly two thirds of melanoma deaths are male. The immune system is known to play a key role in controlling the growth and spread of malignancies, but whether age- and sex-dependent ...
Arditi, Moshe, Crother, Timothy R, Lane, Malcolm E, Luu, Michael, Markman, Janet L, Martinon, Daisy, Noval Rivas, Magali, Porritt, Rebecca A, Posadas, Edwin M, Wakita, Daiko   +9 more
core   +1 more source

The Anti-SLAMF7 Antibody, Elotuzumab, Induces Antibody-Dependent Cellular Cytotoxicity Against CLL Cell Lines

Molecules
SLAMF7, also known as CD319, a SLAM (signaling lymphocytic activation molecule) family receptor, is relatively weakly expressed on chronic lymphocytic leukemia (CLL) B cells.
Dominik Kľoc, Bianca Dubiková, Simona Žiláková, Ján Sykora, Michaela Šuliková, Slavomír Kurhajec, Ján Sabo, Tomáš Guman, Marek Šarišský   +8 more
doaj   +1 more source

Induction of natural killer antibody-dependent cell cytotoxicity and of clinical activity of cetuximab plus avelumab in non-small cell lung cancer. [PDF]

ESMO Open, 2020
Fasano M, Della Corte CM, Di Liello R, Barra G, Sparano F, Viscardi G, Iacovino ML, Paragliola F, Famiglietti V, Ciaramella V, Cimmino F, Capasso M, Iolascon A, Sforza V, Morabito A, Maiello E, Ciardiello F, Morgillo F.   +17 more
europepmc   +1 more source

Therapeutic applications of a novel humanized monoclonal antibody targeting chemokine receptor CCR9 in pancreatic cancer

Molecular Oncology
The relative failure of immune checkpoint inhibitors in pancreatic ductal adenocarcinoma (PDAC) despite having a dense, immunosuppressive tumor microenvironment highlights the need to target alternate/escape pathways.
Hannah G. McDonald, Anna M. Reagan, Charles J. Bailey, Mei Gao, Muqiang Gao, Angelica L. Solomon, Michael J. Cavnar, Prakash K. Pandalai, Mautin T. Barry‐Hundeyin, Megan M. Harper, Justin A. Rueckert, Ángela Turrero, Araceli Tobio, Anxo Vidal, Daniel Roca‐Lema, Elia Álvarez‐Coiradas, Pablo Garrido, Laureano Simón, Joseph Kim   +18 more
doaj   +1 more source

Insights on cytotoxic cells of the colonial ascidian Botryllus schlosseri [PDF]

, 2015
Morula cells (MCs) represent the most abundant circulating hemocyte of the compound ascidian Botryllus schlosseri. They are cytotoxic cells involved in the rejection reaction between contacting, genetically incompatible colonies.
Ballarin, Loriano, Cima, Francesca, Franchi, Nicola   +2 more
core  

The Presence of Antibody-Dependent Cell Cytotoxicity-Mediating Antibodies in Kaposi Sarcoma-Associated Herpesvirus-Seropositive Individuals Does Not Correlate with Disease Pathogenesis or Progression. [PDF]

J Immunol, 2020
Poppe LK, Wood C, West JT.
europepmc   +1 more source

Mechanisms of action and clinical development of elotuzumab [PDF]

, 2017
Colonna, Marco, Ritchie, David
core   +2 more sources